AK

Abdul Khan

Active Director Director DIN 10444426
DIN 10444426 First appointment Dec 2023 Primary industry Paper
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2023
Shareholding value •••• Premium profile

About Abdul Khan

Data last updated:

Abdul Khan is a Director at Arshmaan Pharma Private Limited (since 2023). The company operates in Paper. Arshmaan Pharma Private Limited reported revenue of ₹10.1 Lakh (FY 2025).

DIN 10444426
Primary Designation Director
Industry Paper
First Appointment 28 Dec 2023
Oldest Company Age 2 yrs
Largest company Arshmaan Pharma Private Limited · ₹10.1 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Arshmaan Pharma Private Limited U21000DL2023PTC424537
Director28 Dec 20232023₹10.1 Lakh (FY 2025)Active

Board colleagues of Abdul Khan

NameDINCompanyDesignation
Phool Jahan10444425Arshmaan Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Arshmaan Pharma Private Limited
Premium access

Shareholding and investment profile for Abdul Khan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Abdul Khan

Abdul Khan currently holds 1 directorship: Arshmaan Pharma Private Limited (Director, since 28 Dec 2023, revenue ₹10.1 Lakh (FY 2025)).

Abdul Khan was first appointed on 28 Dec 2023 as Director at Arshmaan Pharma Private Limited.

The current boards of Abdul Khan's companies include Phool Jahan (Arshmaan Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available